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Small, dense low-density lipoproteins (LDL) are predictors of
cardio- and cerebro-vascular events in subjects with the
metabolic syndrome
Abstract
OBJECTIVE: Small, dense low-density lipoproteins (LDL) are a feature of the metabolic syndrome
(MS) but their predictive role still remains to be established. We performed a 2-year follow-up study in
124 subjects with MS (63 +/- 6 years), as defined by the American Heart Association/National Heart,
Lung and Blood Institute guidelines, to assess clinical and biochemical predictors of cerebro- and
cardio-vascular events. METHODS AND RESULTS: Beyond traditional cardiovascular risk factors, we
measured LDL size and subclasses by gradient gel electrophoresis. Clinical events were registered in the
25% of subjects. At univariate analysis subjects with events had increased prevalence of elevated fasting
glucose (P = 0.0117), smoking (P = 0.0015), family history of coronary artery disease (P = 0.0033) and
higher levels of total- and LDL-cholesterol (P = 0.0027 and P = 0.0023, respectively); LDL size was
lower (P < 0.0001), due to reduced larger subclasses and increased small, dense LDL (all P < 0.0001).
At multivariate analysis the following were independent predictors of events (univariate odd ratios were
calculated): low HDL-cholesterol (OR 15.4, P = 0.0238), elevated fasting glucose (OR 12.1, P =
0.0102), elevated small, dense LDL (OR 11.7, P = 0.0004), elevated blood pressure (OR 9.2, P =
0.0392), smoking (OR 4.8, P = 0.0054). CONCLUSIONS: This is the first study that assessed the
predictive role of small, dense LDL beyond traditional cardiovascular risk factors in subjects with MS.
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ABSTRACT 
 
Objective: Small, dense low-density lipoproteins (LDL) are a feature of the metabolic 
syndrome (MS) but their predictive role still remains to be established. We performed a 2-year 
follow-up study in 124 subjects with MS (63±6 years), as defined by the American Heart 
Association/National Heart, Lung, and Blood Institute guidelines, to assess clinical and biochemical 
predictors of cerebro- and cardio-vascular events. Methods and Results: Beyond traditional 
cardiovascular risk factors, we measured LDL size and subclasses by gradient gel electrophoresis. 
Clinical events were registered in the 25% of subjects. At univariate analysis subjects with events 
had increased prevalence of elevated fasting glucose (p=.0117), smoking (p=.0015), family history 
of coronary artery disease (p=.0033) and higher levels of total- and LDL-cholesterol (p=.0027 and 
p=.0023, respectively); LDL size was lower (p<.0001), due to reduced larger subclasses and 
increased small, dense LDL (all p<.0001). At multivariate analysis the following were independent 
predictors of events (univariate odd ratios were calculated): low HDL-cholesterol (OR 15.4, 
p=.0238), elevated fasting glucose (OR 12.1, p=.0102), elevated small, dense LDL (OR 11.7, 
p=.0004), elevated blood pressure (OR 9.2, p=.0392), smoking (OR 4.8, p=.0054). Conclusions: 
This is the first study that assessed the predictive role of small, dense LDL beyond traditional 
cardiovascular risk factors in subjects with MS.  
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INTRODUCTION 
 
Several expert groups have suggested in past years different diagnostic criteria to be used in 
clinical practice to identify subjects with the metabolic syndrome [1-8]. As recently stated by the 
joint American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement on 
“Diagnosis and Management of the Metabolic Syndrome” [8], all the proposed classifications have 
in common the concept that the metabolic syndrome represent a constellation of interrelated risk 
factors of metabolic origin (“metabolic risk factors”) that appear to directly promote the 
development of atherosclerotic cardiovascular disease. Such metabolic risk factors include elevated 
blood pressure, elevated plasma glucose and atherogenic dyslipidemia, which consists of an 
aggregation of lipoprotein abnormalities including elevated plasma triglyceride levels, reduced 
high-density-lipoproteins (HDL)-cholesterol concentrations and increased small, dense low-density-
lipoproteins (LDL) [9,10]. 
In fact, a number of recent evidences suggest that the “quality” rather than only the 
“quantity” of LDL exerts a direct influence on the cardiovascular risk (reviewed in [11]): LDL 
comprise multiple distinct subclasses that differ in size, density, physicochemical composition, 
metabolic behaviour and atherogenicity [12]. There are at least four major subspecies of LDL (e.g., 
large LDL-I, medium LDL-II, small LDL-III, very small LDL-IV) and the predominance of small 
dense LDL have been accepted as an emerging cardiovascular risk factor by the National 
Cholesterol Education Program Adult Treatment Panel III [3].  
On the basis of available evidences [13-16], the above mentioned Scientific Statement [8] 
identified the presence of small, dense LDL as associated with the metabolic syndrome but in need 
of more research. Recent studies [17-19] further suggested that small, dense LDL may represent a 
valuable marker for diagnosis and severity of the metabolic syndrome but its predictive role still 
remains to be established. Therefore, we performed a 2-year follow-up study to assess potential 
clinical and biochemical predictors of cerebro- and cardio-vascular events in a group of subjects 
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with the metabolic syndrome without overt coronary artery disease (CAD); particularly, we aimed 
to assess in such patients the potential predictive role of small, dense LDL, beyond that of 
traditional established cardiovascular risk factors (e.g. older age, male gender, hypertension, 
diabetes, obesity, smoking, family history of cardiovascular diseases, dyslipidemia). 
 
MATERIALS AND METHODS 
 
Patients and control subjects 
We designed a prospective 2-year follow-up study for subjects with the metabolic syndrome 
without overt CAD. In order to recruit them, we evaluated approximately 1,000 subjects undergoing 
contrast angiography during a period of six months at the Angiographic Unit of the Villa Maria 
Eleonora Hospital of Palermo, Italy. At admission all subjects underwent a medical examination 
including a blood test, and also answered a questionnaire on personal and medical items, including 
age, past medical history and use of medications. The adopted procedures were in agreement with 
the Helsinki Declaration of 1975, as revised in 1983. The study protocol was reviewed and 
approved by the Ethical Committee of Villa Maria Eleonora Hospital, Italy and all patients gave 
their written consent to participate in the study. 
The inclusion criteria was the presence of the metabolic syndrome as defined by the joint 
American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [8], e.g. 
the presence of any three of the following five risk factors: elevated waist circumference (>88 cm in 
women and >102 cm in men), elevated fasting triglycerides (≥150 mg/dL or on drug treatment for 
elevated triglycerides), reduced HDL-cholesterol (<50 mg/dL in women and <40 mg/dL in men or 
on drug treatment for reduced HDL-cholesterol), elevated blood pressure (systolic blood pressure 
≥130 mm Hg or diastolic blood pressure ≥85 mm Hg or on antihypertensive drug treatment in a 
patient with a history of hypertension), and elevated fasting glucose (≥100 mg/dL or on drug 
treatment for elevated glucose). 
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We found 732 subjects with the metabolic syndrome potentially eligible for our study 
without using any age or gender criteria for exclusion. We preliminary excluded subjects with overt 
CAD, as determined by contrast angiography. The grade of segmental coronary stenosis was ranked 
according to the joint classification of American Heart Association/American College of 
Cardiology [20] in (I) irregular wall outline (<25% stenosis); (II) slight stenosis (25–50%); (III) 
moderate stenosis (51–74%); (IV) hemodynamically relevant stenosis (75–89%); (V) subtotal 
stenosis (90–99%) and (VI) vascular occlusion (100%). We included in the present study subjects 
with grade I only. We also excluded patients with presence of inflammatory state and renal or 
hepatic diseases able to modify plasma lipoproteins and those using beta blockers. 
According to these exclusion criteria, after giving informed written consent, we were able to 
include in our study 124 patients, 68 men and 56 women. As controls, we selected a group of 102 
subjects without the metabolic syndrome and overt CAD, matched for gender and age with the same 
exclusion criteria described above, who underwent contrast angiography during the same period at 
the Angiographic Unit. Controls were mainly included in the study in order to calculate the 
prevalence of elevated small, dense LDL (see below). Body mass index (BMI) was calculated as 
kg/m2. 
 
Biochemical analyses 
A blood sample was collected from each subject after 12-14 hours overnight fast in sodium-
EDTA tubes before the angiography. Total cholesterol, triglycerides and HDL-cholesterol were 
quantified by standard enzymatic-colorimetric methods [21,22] and LDL-cholesterol was calculated 
by the Friedewald formula. Plasma lipids were analyzed from EDTA plasma at the Diagene 
laboratories Inc. (Reinach, Basel, Switzerland), which is a Swiss routine and research laboratory, 
certified by the Swiss Commission for Quality Control in Medical Laboratories, participating in the 
periodical ring tests carried out by the Quality Control Centre Switzerland. Wet chemistry analyses 
were performed on a Microlab 300 Chemistry Analyzer from Vital Diagnostics (Clinical Data Inc., 
 5
Newton, MA, USA) using Ecoline® reagents from VWR (VWR International, Dietikon, 
Switzerland); HDL cholesterol was precipitated using magnesium phosphotungstate [23].  
 
Nondenaturing polyacrylamide gradient gel electrophoresis 
Nondenaturing polyacrylamide gradient gel electrophoresis (GGE) of plasma was performed 
in Switzerland in the laboratory of K.B. at 10-14°C in 2-16% polyacrylamide gradient gels. Gels 
were subjected to electrophoresis for 24 h at 125 V in tris borate buffer (pH 8.3) as described 
elsewhere [24,25]. Gels were fixed and stained for lipids in a solution containing oil red O in 60% 
ethanol at 55°C. Gels were placed on a light source and photographed using a Luminescent Image 
Analyzer, LAS-3000 of Fujifilm, detection using white transmitted light source.  Migration distance 
for each absorbance peak was determined and the molecular diameter corresponding to each peak 
was calculated from a calibration curve generated from the migration distance of size standards of 
known diameter, which includes carboxylated latex beads (Duke Scientific, Palo Alto, CA), 
thyroglobulin and apoferritin (HMW Std, Pharmacia, Piscataway, NJ) having molecular diameter of 
380 Å, 170 Å and 122 Å, respectively, and lipoprotein calibrators of previously determined particle 
size. LDL subclass distribution (LDL I, IIA, IIB, IIIA, IIIB, IVA and IVB) as percentage of total 
LDL was calculated as previously described [24]. Levels of small, dense LDL were considered to 
be increased in those patients with values greater than mean +2 SD of the values of controls (e.g., 
subjects without the metabolic syndrome), as already described [23]. 
 
Follow-up 
We performed a 2-year follow-up study in subjects with the metabolic syndrome in order to 
evaluate cerebro- and cardio-vascular morbidity and mortality and to assess if baseline clinical and 
laboratory variables were predictive of clinical events. Regarding the use of cardiovascular 
medications, during the follow-up patients received treatment with anti-hypertensive drugs (58%), 
anti-diabetic drugs (35%) and lipid-lowering drugs (41%). There was no death during the follow-up 
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period and vascular events were registered in the 25% of patients and included: transient ischemic 
attack, stroke, acute myocardial infarction, coronary revascularizations. Cerebro-vascular disease 
was defined as a self-reported stroke with positive computer tomography and transient ischemic 
brain attack was defined as a brain deficit caused by vascular disease that clear completely in less 
than 24 hours. Acute myocardial infarction was defined by a prolonged episode of chest pain with 
EKG and/or specific myocardial enzymes changes, involving hospitalization.  
 
Statistical analysis 
Statistical analysis for univariate comparisons were performed using χ2 test (for nominal 
variables) and unpaired Student’s t-test (for numeric variables) (see Tables 1-2). ANOVA was used 
to test the difference in LDL size in relation to the number of components of the metabolic syndrome 
(see Figure 1). Correlation analyses were performed using the Spearman rank correlation method 
(see Figure 2). Multivariate analysis was performed by logistic regression in order to assess 
possible clinical and laboratory variables independently associated with the cardiovascular events, 
as registered during the 2-years follow-up (see Table 3); univariate odd ratios were calculated. 
Calculations were performed using Stat View® 5.0 (SAS Institute Inc., Cary, NC, USA). 
 
RESULTS 
 
As shown in Table 1, subjects with the metabolic syndrome and controls were matched for 
age and gender. As expected, in relation to controls, subjects with the metabolic syndrome had 
higher prevalence of each individual component of the syndrome with the only exception of similar 
prevalence of elevated triglycerides (or on drug therapy for them). Subjects with the metabolic 
syndrome also showed increased prevalence of smoking and family history of CAD (both p<.0001), 
reduced HDL-cholesterol concentrations (p<.0001) as well as lower LDL size (p<.0001), due to a 
reduction in large LDL-I particles (p=.0002) with a concomitant increase in small, dense LDL-IIIA 
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(p<.0001), -IIIB (p=.0006) and –IVB (p=.0023). Therefore, elevated levels of total small, dense 
LDL were higher in subjects with the metabolic syndrome vs. controls (p<.0001). Figure 1 shows 
the distribution of LDL size in relation to the number of components of the metabolic syndrome. 
In the two-year follow-up period vascular events were registered in the 25% of patients; 
these subjects showed (see Table 2) higher prevalence of elevated fasting glucose (or on drug 
therapy) (p=.0117), smoking (p=.0015), family history of CAD (p=.0033) as well as higher levels of 
total- and LDL-cholesterol (p=.0027 and p=.0023, respectively). LDL size was lower (p<.0001), 
due to a reduction in larger LDL-I and –IIA (both p<.0001) with a concomitant increase in all small, 
dense subclasses: LDL-IIIA, -IIIB, -IVA and -IVB (all p<.0001). Levels of total small, dense LDL 
were found elevated in all subjects with events vs. the 24% of those event-free (p<.0001). 
Correlation analysis was performed in order to assess potential relationships between BMI 
and all lipid parameters. Regarding plasma lipids, BMI was correlated only with LDL-cholesterol 
(r=+.145, p=.0290, data not shown). We also found an inverse correlation between BMI and LDL 
size (r= -.261, p<.0001, see Figure 2); regarding LDL subclasses, BMI correlated inversely with 
LDL-IA (r=-.154, p=.0203), and positively with LDL-IIIA (r=.134, p=.0447) (data not shown). 
Logistic regression analysis was performed in subjects with the metabolic syndrome to test 
whether baseline clinical and laboratory variables were independently associated with the vascular 
events (Table 3) and we found the following independent predictors: low HDL-cholesterol (or on 
drug therapy) (OR 15.4, p=.0238), elevated fasting glucose (or on drug therapy) (OR 12.1, p=.0102), 
elevated small, dense LDL (OR 11.7, p=.0004), elevated blood pressure (or on drug therapy) (OR 
9.2, p=.0392), smoking (OR 4.8, p=.0054). We also found by logistic regression analysis that  BMI 
alone did not predict event rates or the prevalence of elevated levels of small, dense LDL in subjects 
with the metabolic syndrome (data not shown). 
 
DISCUSSION 
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Atherogenic dyslipidemia, is strongly associated with the metabolic syndrome but scientific 
guidelines support so far recommendations to manage HDL-cholesterol and triglyceride 
concentrations only and not levels of atherogenic small, dense LDL [8]. Yet, available evidence 
suggests that small, dense LDL may be independently associated with the metabolic syndrome. 
Haffner et al. already showed in 1995 that LDL size was decreased in subjects with multiple 
metabolic disorders [13]; Hulthe et al. [14] further assessed that LDL size was significantly smaller 
in subjects with the metabolic syndrome, in relation to those without it, using the WHO definition 
[1]. We extended in the present study such observations, showing a clear significant association 
between LDL peak particle size and number of components of the metabolic syndrome, as assessed 
by the joint American Heart Association/National Heart, Lung, and Blood Institute Scientific 
Statement [8]. 
Recent studies [17-19] also suggested that small, dense LDL may represent a valuable 
marker for diagnosis and severity of the metabolic syndrome. Using the Lipoprint system Gazi et al. 
[17] showed that subjects with the metabolic syndrome exhibit significantly higher concentrations 
of small, dense LDL than individuals who do not fulfill the criteria for such syndrome. Using a 
different and more detailed methodology we here confirmed that small, dense LDL were reduced in 
our subjects with the metabolic syndrome and further showed that such reduction was confined in 
the LDL-IIIA, -IIIB and IVB subclasses. Previous studies suggested a central role of triglycerides in 
determining such levels of small, dense LDL [17-19].   
LDL size and subclasses are altered in patients with the metabolic syndrome but it is still 
unknown if such alterations may significantly increase their cardiovascular risk. This is the first 
study that aimed to clarify this point. We performed a two-year follow-up study to assess potential 
clinical and biochemical predictors of vascular events in a group of subjects with the metabolic 
syndrome without overt CAD. Cardio- and cerebro-vascular events were registered in the 25% of 
patients; these subjects showed higher prevalence of most of the traditional cardiovascular risk 
factors as well as lower LDL size due to a reduction in larger particles with a concomitant increase 
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in all small, dense LDL subclasses. Notably, levels of small, dense LDL were found elevated in all 
subjects with vascular events.  
The role of small, dense LDL was highlighted in the present study by multivariate analysis. 
We performed logistic regression in order to asses possible independent associations between 
clinical and laboratory variables and vascular events. Beyond confirming that some of the 
components of the syndrome show an independent predictive role (e.g. low HDL-cholesterol, 
elevated fasting glucose, elevated blood pressure), we also found that elevated small, dense LDL 
were independently associated with the events (OR 11.7, p=.0004). Notably, among all lipid 
variables (that also included high triglycerides and high LDL-cholesterol), only low HDL-
cholesterol and elevated small, dense LDL reached the statistical significance. This suggests that 
more than the traditional lipids may be taken into account in this category of high-risk patients for a 
better management of their disease. 
However, future prospective studies with larger sample size are needed to confirm this 
preliminary observation and, if so, whether therapy focused on raising HDL-cholesterol as well as 
on reducing triglyceride and small, dense LDL levels may lower the incidence or progression 
vascular diseases. It is known that the therapeutical modulation of low HDL-cholesterol and high 
triglycerides significantly reduce cardiovascular risk [3] and lipid-lowering agents are also effective 
in reducing levels of small, dense LDL [26-28]. Dietary management is also of importance in such 
category of high-risk subjects [29,30]. Notably, we found that BMI values were comparable 
between subjects with the metabolic syndrome and controls. This finding suggest that in the present 
study we compared two matched groups of equal degree of obesity, one having the metabolic 
syndrome, the other not fulfilling the criteria. Of interest, BMI alone did not predict event rates or 
the prevalence of small, dense LDL in subjects with the metabolic syndrome. 
In conclusion, this is the first study that evaluated the predictive role of small, dense LDL 
beyond traditional cardiovascular risk factors in subjects with the metabolic syndrome and without 
overt CAD. We preliminary confirmed that small, dense LDL is a feature of the metabolic 
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syndrome and further showed an independent predictive role for future cardio- and cerebro-vascular 
events. These findings may have potentially important consequences on the assessment and 
management of atherogenic dyslipidemia in this category of high-risk patients but should be 
confirmed by future prospective studies with larger sample size. It has been recently suggested that 
the therapeutical modulation of high triglycerides, low HDL-cholesterol and increased levels of 
small, dense LDL (the so-called “atherogenic lipoprotein phenotype” [9,10]) is probably one of the 
most effective methods of reducing cardiovascular risk [31-32]. 
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FIGURES LEGEND 
 
Figure 1. Distribution of LDL peak particle size in relation to the number of components of the 
Metabolic Syndrome, as defined by the joint American Heart Association/National Heart, Lung, 
and Blood Institute Scientific Statement [8] (p<.0001 by ANOVA). 
Figure 2. Spearman correlation between BMI and LDL size in all subjects. 
 
Table 1. Clinical and laboratory characteristics in all subjects. Results are shown as mean±SD. 
MS: metabolic syndrome. In bold the five criteria for the definition of MS [8]. 
 Without MS 
 (n=102) 
 
p= 
 
With MS 
 (n=124) 
Elevated waist circumference, n (%) 11 (11) <.0001 49 (40) 
Elevated blood pressure (or on drug therapy), n (%) 21 (21) <.0001 82 (66) 
Elevated fasting glucose (or on drug therapy), n (%) 16 (16) <.0001 52 (42) 
Elevated triglycerides (or on drug therapy), n (%) 15 (15) ns 16 (13) 
Low HDL-cholesterol (or on drug therapy), n (%) 16 (16) <.0001 64 (52) 
Age (years)    63±8 ns 63±6 
Male gender, n (%) 60 (59) ns 68 (55) 
BMI (kg/m2) 28±3 ns 28±3 
Smoking, n (%) 11 (11) <.0001 50 (40) 
Family history of cardiovascular diseases, n (%) 16 (16) <.0001 52 (42) 
Total-cholesterol (mg/dL) 180±26 ns 172±41 
Triglycerides (mg/dL) 111±41 ns 103±44 
HDL-cholesterol (mg/dL) 51±10 <.0001 44±9 
LDL-cholesterol (mg/dL) 107±24 ns 108±36 
LDL size (Å) 274±6 <.0001 266±8 
LDL-I (%) 34±6 .0002 30±10 
LDL-II A (%) 20±3 ns 19±1 
LDL-II B (%) 18±3 ns 17±5 
LDL-III A (%) 11±2 <.0001 14±5 
LDL-III B  (%) 5±1 .0006 6±3 
LDL-IV A (%) 6±2 ns 7±3 
LDL-IV B (%) 6±2 .0023 7±4 
High small, dense LDL (LDL-III + -IV), n (%) 5 (5) <.0001 53 (43) 
 18
 19
Table 2. Clinical and laboratory characteristics in subjects with the Metabolic Syndrome in 
relation to the vascular events registered during the follow-up. Results are shown as mean±SD. 
In bold the five criteria for the definition of the metabolic syndrome [8]. 
 No events 
(n=93) 
p= With events 
(n=31) 
Elevated waist circumference, n (%) 35 (38) ns 14 (45) 
High small, dense LDL (LDL-III + -IV), n (%) 
Elevated blood pressure (or on drug therapy), n (%) 61 (66) ns 21 (68) 
Elevated fasting glucose (or on drug therapy), n (%) 33 (35) .0117 19 (61) 
Elevated triglycerides (or on drug therapy), n (%) 11 (12) ns 5 (16) 
Low HDL-cholesterol (or on drug therapy), n (%) 44 (47) ns 20 (65) 
Age (years)    64±6 ns 62±7 
Male gender, n (%) 53 (57) ns 15 (48) 
BMI (kg/m2) 28±2 ns 29±3 
Smoking, n (%) 30 (32) .0015 20 (65) 
Family history of cardiovascular diseases, n (%) 32 (34) .0033 20 (65) 
Total-cholesterol (mg/dL) 153±43 .0027 178±39 
Triglycerides (mg/dL) 104±41 ns 100±52 
HDL-cholesterol (mg/dL) 44±9 ns 43±9 
LDL-cholesterol (mg/dL) 91±35 .0023 114±35 
LDL size (Å) 268±6 <.0001 260±10 
LDL-I (%) 36±10 <.0001 23±7 
LDL-II A (%) 20±4 <.0001 16±3 
LDL-II B (%) 17±5 ns 16±3 
LDL-III A (%) 12±4 <.0001 18±5 
LDL-III B  (%) 5±2 <.0001 7±3 
LDL-IV A (%) 5±2 <.0001 10±3 
LDL-IV B (%) 
22 (24) 
5±3 <.0001 10±4 
<.0001 31 (100) 
Table 3. Logistic regression analysis of independent associations of baseline clinical and laboratory characteristics with the vascular events in subjects 
with the Metabolic Syndrome. In bold the five criteria for the definition of the metabolic syndrome [8]. 
 
Logistic Regression Analysis  
OR (95% CI); p-value  
 
 ns Elevated waist circumference  
 9.2 (1.7-15.0), .0392 Elevated blood pressure (or on drug therapy)
 
12.1 (3.1-19.6), .0102 Elevated fasting glucose (or on drug therapy)  
 ns High Triglycerides (or on drug therapy) 
 
15.4 (2.5-22.9), .0238  Low HDL-cholesterol (or on drug therapy) 
 
ns Age (x10 years)     
 ns Male gender 
 
4.8  (1.3-12.3), .0054 Smoking  
 
ns Family history of cardiovascular diseases  
 ns High LDL-cholesterol (>100 mg/dL) 
 
High small, dense LDL (LDL-III + -IV) 11.7 (3.2-24.1), .0004  
 
 
